Abstract
Natriuretic peptides, produced by cardiac myocytes, are regulators of the intravascular volume and blood pressure, and also exhibit neuroendocrine, metabolic and growth controlling effects. In heart failure, their synthesis increases exponentially as part of the neuroendocrine activation, but their beneficial effects are diminished. The paper reviews relevant data about their role as diagnosis and prognosis markers in heart failure, the hemodynamic and clinical benefits of their use as therapy in heart failure, together with the main adverse effects. Peptides non-specifically increase in extracardiac pathology and the literature reveals the mechanisms of increase, significance and threshold values to exclude cardiac dysfunction.
Keywords: Natriuretic peptides, heart failure, nesiritide, sacubitril- valsartan, cardiovascular diseases, cardiac dysfunction.
Graphical Abstract
[1]
Ponikowski P, Voors AA, Anker SA, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure; The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC); developed with the special contribution of the Heart Failure Association of the ESC. Eur Heart J 2016; 37(27): 2129-200.
[2]
Potter LR, Yoder AR, Dickey DM. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; 191: 341-66.
[3]
Kisch B. Electron microscopy of the atrium of the heart in guineo pig. Exp Med Surg 1856; 14: 99-112.
[4]
Jamielson JD, Palade GE. Specific granules in atrial muscle cells. J Cell Biol 1964; 23: 151-72.
[5]
De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
[6]
Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
[7]
Mukuyoma M, Nakao K, Hosada K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
[8]
Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: Physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17-29.
[9]
Best PJM, Burnett Jr JC, Wilson SH, et al. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55(2): 375-84.
[10]
Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment. Clin Sci (Lond) 2017; 130(2): 57-77.
[11]
Meems LMG, Burnett Jr, JC. Innovative therapeutics designer natriuretic peptides. J Am Coll Cardiol 2016; 1(7): 557-67.
[12]
Schlueter N, de Sterke A, Willmes DM, et al. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol Ther 2014; 144(1): 12-27.
[13]
Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: A new lipolytic pathway in human adipocytes. FASEB J 2000; 14: 40409-15.
[14]
Redfiield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40(5): 976-82.
[15]
Davis KM, Fish LC, Minaker KL, Elahi D. Atrial natriuretic peptide levels in the elderly: Differentiating normal aging changes from disease. J Gerontol A Biol Sci Med Sci 1996; 51(3): M95-M101.
[16]
Thygesen K, Mair J, Mueller C, Huber K, Weber M. ESC Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. EHJ 2012; 33(16): 2001-6.
[17]
Clerico A, Zucchelli GC, Pilo A, Emdin M. Clinical relevance of biological variation of B type natriuretice peptide. Clin Chem 2005; 51(5): 925-6.
[18]
Hamasaki H. The effects of exercise on natriuretic peptides in individuals without heart failure. Sports (Basel) 2016; 4(2): 32.
[19]
1 Diez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail 2017; 19(2): 167-76.
[20]
Roberts E, Ludman AJ, Worzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta analysis in the acute setting. BMJ 2015; 350: h910.
[21]
Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002; 8(3): 149-54.
[22]
Doust JA, Pietrzak E, Dobson A, Glaszion P. How well does B type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. BMJ 2005; 330(74921): 625.
[23]
Richards AM, Doughty R, Nicholls MG, et al. Plasma N terminal proBNP and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction, Australia- New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37: 1781-7.
[24]
Troughton RW, Richards M. B type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009; 2(2): 216-25.
[25]
Y. Iwanaga I, Nishi S, Furuichi S, et al. B type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: Comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47(4): 742-8.
[26]
Troughton RW, Prior DL, Pereira JJ, et al. Plasma B type natriuretic peptide levels in systolic heart failure. J Am Coll Cardiol 2004; 43(3): 416-22.
[27]
Lubien E, de Maria A, Krishnaswamy P, et al. Utility of B natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
[28]
Abhayaratna WP, Marwick TH, Becker NG, et al. Population based detection of systolic and diastolic dysfunction with aminoterminal proB type natriuretic peptide. Am Heart J 2006; 152(5): 941-8.
[29]
Krupicka J, Janota T, Kasalova Z, Hradec J. Natriuretic peptides- physiology, pathophysiology and clinical use in heart failure. Physiol Res 2009; 58: 171-7.
[30]
Krupicka J, Janota T, Hradec J. Natriuretic peptides in heart failure. Cor et Vasa 2013; 75(4): e370-96.
[31]
Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration – randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138(6Pt1): 1126-32.
[32]
Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal BNP (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
[33]
Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide guided therapy on hospitalization or cardiovascular mortality in high risk patients with heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2017; 318(8): 713-20.
[34]
Gong B, Wu Z, Li Z. Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomized trials. BMJ Open 2016; 6(1)e008545
[35]
O’ Connor CM, Starling RC, Hernandez AF, et al. ASCEND trial -Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
[36]
Sackner Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111(12): 1487.
[37]
Chen HH, Anstrom KJ, Givertz MM, et al. Low dose dopamine or low dose nesiritide in acute heart failure with renal dysfunction, the ROSE acute heart failure randomized trial. JAMA 2013; 310(23): 2533-43.
[38]
Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and preexisting renal dysfunction a randomized double blind placebo controlled clinical trial. J Am Coll Cardiol 2007; 50: 1835.
[39]
N.S. Lee,, L.B. Daniels. Current understanding of the compensatory actions of cardiac natriuretic peptides in cardiac failure a clinical perspective. Card Fail Rev 2016; 2(1): 14-9.
[41]
Langenickel TH, Tsubouchi C, Ayalasomayajula S, et al. The effect of LCZ 696 (sacubitril/valsartan) on amyloid beta concentrations in cerebrospinal fluid of healthy subjects. Br J Clin Pharmacol 2016; 81: 878-90.
[42]
Cannon JA, Shen L, Jhund PS, et al. On behalf of the PARADIGM- HF Investigators and Committees. Dementia related adverse events in PARADIGM- HF and other trials in heart failure with reduced ejection frcation. Eur J Heart Fail 2017; 19(1): 129-37.
[43]
Biering-Sorensen T, Shah A, Claggett B, et al. The angiotensin receptor blocker- neprilysin inhibitor sacubitril/valsartan improves left ventricle myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). J Am Coll Cardiol 2018; 71(11): A2665.
[44]
Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor- neplilysin inhibition in heart failure with preserved ejection fraction: Rationale and design of the PARAGON –HF Trial. JACC Heart Fail 2017; 5(7): 471-82.
[45]
Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: A systematic review. Intensive Care Med 2008; 34: 2147-56.
[46]
Kontos MC, Lanfear DE, Spertus JA, et al. Prognostic value of serial N terminal pro brain natriuretic peptide testing in patients with acute myocardial infarction. Am J Cardiol 2017; 120(2): 181-5.
[47]
D. Farmakis G, Filippatos M,, Tubaro M,, et al. Natriuretic peptides in acute coronary syndromes prognostic value and clinical implications. Congest Heart Fail 2008; 14(4)(Suppl. 1): 25-9.
[48]
Marsiliani D, Buccelletti F, Carroccia A, et al. Natriuretic peptides and atrial fibrillation. Eur Rev Med Pharmacol Sci 2010; 14: 855-60.
[49]
Richards M, Di Somma S, Mueller C, et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients. Results from the BACH Study (Biomarkers in Acute Heart Failure). J Am Coll Cardiol 2013; 1: 192-9.
[50]
Goetze JP, Jensen G, Mollar S, Bendtsen F, Rehfeld JF, Henriksen JM. BNP and N terminal pro BNP are both extracted in the normal kidney. Eur J Clin Invest 2006; 36: 8-15.
[51]
Austin WJ, Bhalla V, Hernandez- Arce I,, et al. Correlation of prognostic utility of B type natriuretic peptide and its amino terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506-12.
[52]
Santos Araujo C, Leite Moreira A, Pestana M. Clinical value of natriuretic peptides in chronic kidney disease. Nefrologia 2015; 35(3): 227-33.
[53]
De Filippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53: 1511-9.
[54]
Rudiger A, Fischler M, Harpes P, et al. In critically ill patients, BNP and amino terminal – pro BNP correlate with C reactive protein values and leukocyte counts. Int J Cardiol 2008; 126(1): 28-31.
[55]
Brueckmann M, Borggrefe M. Natriuretic peptide testing for risk stratification of critically ill patients. E J Cardiol Pract 2006; 5(14): 3.
Article Metrics
67
3
1
1